Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-290-3 | CAS number: 161907-80-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The NOAEL in a 28 day rat study was approximately 380 mg B-TTEGME/kg bw/day based upon a toxicity study with Brake fluid up to 1000 mg/kg bw/day. No adverse findings were observed up to highest dose level. The study can be used to define an interim DNEL for hazard characterization until data from the proposed 90d study become available.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 380 mg/kg bw/day
Additional information
The repeated dose toxicity of B-TTEGME was studied by read-across with data from Brake Fluid DOT 4 containing B-TTEGME. Similarity with B-TTEGME was based on a common functional group, common precursors an/or likelihood of common breakdown products and common constituents, as also described in a separated justification document in Section 13.
An oral subacute toxicity study (28 days) was performed with abrake fluidcontaining 38% B-TTEGME,of which ca. 45% was B-TEGME, corresponding with 17% B-TEGME in the tested brake fluid (Shell, 1993a). The test material was administered to rats at doses of 9.5, 57 and 380 mg B-TTEGME/kg bw/day, based upon doses of 25, 150 and 1000 mg brake fluid/kg bw/day. This study was conducted according to OECD 407 guideline and in compliance with GLP, therefore it was considered to be adequate, reliable and relevant. As it was performed with a brake fluid containing 38 % B-TTEGME, it was considered as a support study, and a 90 -day repeated dose toxicity study is proposed (see further). Dosing did not result in treatment related clinical signs, effects on body weight, clinical chemistry, haematology, gross pathology, organ weights and urinalysis. The only finding related to treatment was a very slight hepatocellular centrilobular hypertrophy at histology in males and some females at 380 mg B-TTEGME/kg/day or 1000 mg brake fluid/kg bw/day. Liver weight increases at this high dose compared to controls were approximately 7% in males and 3% in females. Considering the mild nature of the findings, and in the absence of any other relevant treatment related effect, this was not considered to constitute an adverse effect. The NOAEL was therefore considered to be at least 380 mg B-TTEGME/kg bw/day or 1000 mg brake fluid/kg bw/day. The other borated and non-borated glycol ethers and components present in the brake fluids also might have contributed to the findings.
Liver effects such as liver weight increase and histopathological hepatocellular hypertrophy in experimental animals have been described in literature (Andrew, 2005) as frequently observed and adaptive effects, often related to enzyme induction and metabolic breakdown of the products in the liver. A liver weight increase of <10% is generally considered to be non-adverse, while increases of 10% or more are interpreted as being potentially adverse. Liver enlargement associated with an increase in the activity of xenobiotic metabolising enzymes is an adaptation to increased functional load, and is therefore considered to be a physiological rather than a pathological response or adverse effect.
A 3 -month repeated dose toxicity with B-TTEGME was not available, but 90-day oral repeated dose toxicity study with B-TEGME has been proposed by the BGE Consortium. Based on the close structure similarity and similar toxicological profile of both borated glycol ethers, the study with B-TEGME is considered relevant to use from a read across viewpoint. Based upon the data from physicochemical and basic pharmacokinetic assessment, and based upon the 28 -day toxicity study with brake fluid, oral dosingis regarded as the most relevant route of administration for testing. The results of the 90 -day study will be important to decide on further testing or weight of evidence/waiving strategy with regard to reproductive toxicity, as separately described under the other sections (7.8.1 and 7.8.2) and the toxicology testing strategy document (attached).
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: liver
Justification for classification or non-classification
As there are no adverse effects seen up to the doses tested, there is no need for classification. A slight effect was observed in the liver, however this was considered to be a physiological adaptive effect related to metabolism at high dosages.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.